Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial | Zendy

Ahmed Mahmoud | Zendy; Karen P. Hayhurst | Zendy; Richard Drake | Zendy; Shôn Lewis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled Trial

Author(s) -

Ahmed Mahmoud,

Karen P. Hayhurst,

Richard Drake,

Shôn Lewis

Publication year - 2011

Publication title -

schizophrenia research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.464

H-Index - 7

eISSN - 2090-2085

pISSN - 2090-2093

DOI - 10.1155/2011/596898

Subject(s) - sexual function , quality of life (healthcare) , sexual dysfunction , schizophrenia (object oriented programming) , antipsychotic , medicine , psychiatry , adverse effect , clinical psychology , nursing

The impact of antipsychotic drug treatment on sexual function was investigated during a randomised trial comparing first generation antipsychotics (FGAs) to (nonclozapine) second generation antipsychotics (SGAs). Sexual function and quality of life were (rater-blind) assessed in 42 patients with DSM-IV schizophrenia (aged 18–65) using the self-report version of the Derogatis Interview for Sexual Function (DISF-SR) and the Heinrichs Quality of Life Scale (QLS), prior to, and 12 weeks following, a change in medication from an FGA drug to either an FGA or SGA drug. SGAs significantly improved sexual function compared to FGAs. Change in sexual function was associated with change in quality of life. Where impaired sexual functioning is a distressing adverse effect of treatment with an FGA agent, consideration should be given to switching to an SGA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research